Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,400.27
    -899.46 (-1.72%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Behind the brand:

'Boutique hotel at sea': Virgin Voyages CEO hails Branson's 'biggest endeavour'

On board entrepreneur's latest venture

How one founder tapped lasers to automate and scale stem cell production

Darrell Etherington
Updated ·1-min read

Not only is this week's guest the TechCrunch Disrupt 2021 Battlefield winner, but Nabiha Saklayen is also democratizing access to life-saving cell therapies by using — you guessed it — lasers. Saklayen is the co-founder and CEO of Cellino, which is a company developing the tech to automate stem cell production that will lower the cost of cell therapies and increase the yield of viable cells. In this episode, Saklayen tells Jordan and Darrell how she built a startup beginning with the tech and finding a business fit, her evolving leadership style and why this work is crucial to the biomedical field.

Take our listener survey and let us know a bit about yourself and what you think of FOUND.

Connect with us: